Related Experiment Video
Updated: Dec 28, 2025
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
18.7K
Comprehensive Proteomic Characterization Reveals Subclass-Specific Molecular Aberrations within Triple-negative
Max Kosok1, Asfa Alli-Shaik2, Boon Huat Bay3
1Institute of Molecular and Cell Biology, Agency for Science, Technology and Research, Singapore 138673, Singapore; Department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117594, Singapore.
Iscience
|February 15, 2020
Summary
Triple-negative breast cancer (TNBC) is aggressive and lacks targeted therapies. This study identifies distinct proteome profiles and specific therapeutic targets for basal A and basal B TNBC subclasses.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype.
- TNBC lacks targeted therapies due to its molecular heterogeneity.
- Subclassification of TNBC is crucial for developing effective treatments.
Purpose of the Study:
- To identify distinct proteome expression profiles for TNBC subclasses.
- To uncover subclass-specific molecular aberrations and therapeutic targets.
- To differentiate therapeutic strategies for basal A and basal B TNBC.
Main Methods:
- In-depth proteomics analysis of breast cancer cells.
- Identification of proteome expression profiles for TNBC subclasses.
- Analysis of protein-protein interaction and co-regulation networks.
Main Results:
- Kinases and proteases show unique expression patterns in basal A and basal B TNBC.
- Dysregulated pathways and plausible targets were identified for each subclass.
- Specific targets for the aggressive basal B subclass include kinases AXL, PEAK1, TGFBR2 and proteases FAP, UCHL1, MMP2/14.
Conclusions:
- TNBC exhibits intricate molecular mechanisms that vary between subclasses.
- Therapeutic strategies for TNBC should be subclass-specific.
- Targeting specific kinases and proteases offers potential for basal B TNBC treatment.
